Developing AI based mobile applications that identify genetic disorders
in pediatric patients

twenty20_f55c0920-f6ca-4442-a153-27deacf93ed3

beautiful-happy-young-family-with-two-children-in-a-field-in-summer-daughter-with-down-syndrome-in-a_t20_wLzB0e

0 million

Children a year are born with chromosomal abnormalities; many never receiving adequate treatment or diagnosis

portrait-of-cute-baby-boy-with-down-syndrome_t20_rolXeg

0,000

Newborn babies die globally due to congenital disorders within four weeks of their birth

Through early detection, newborn deaths and hospitalizations can be significantly reduced.

Developing AI based mobile applications that identify genetic disorders
in pediatric patients

0 million

Children a year are born with chromosomal abnormalities; many never receiving adequate treatment or diagnosis

0,000

Newborn babies die globally due to congenital disorders within four weeks of their birth

Through early detection, newborn deaths and hospitalizations can be significantly reduced.

Developing AI based mobile applications that identify the phenotypes of genetic disorders
in pediatric patients

0 million

Children a year are born with chromosomal abnormalities; many never receiving adequate treatment or diagnosis

0,000

Newborn babies die globally due to congenital disorders within four weeks of their birth

Through early detection, newborn deaths and hospitalizations can be significantly reduced.

MGeneRx is developing an artificial intelligence platform developed by rare disease experts, physicians and engineers that can instantly identify a child’s risk for congenital birth defects using biometric analysis.

Our Approach

With over 8,000 identified genetic disorders, current common newborn DNA tests only detect approximately 20 of them. We are working to address this by developing cost effective screening that identifies the phenotypes of genetic anomalies.

twenty20_fae7010c-a943-4731-8fd4-12dd27739782

Our application was evaluated on thousands of pediatric patients from 28 countries with 128 different genetic conditions

With over 8,000 identified genetic disorders, current common newborn DNA tests only detect approximately 20 of them. We are working to address this by developing cost effective screening that identifies the phenotypes of genetic anomalies.

Our application was evaluated on thousands of pediatric patients from 28 countries with 128 different genetic conditions

With over 8,000 identified genetic disorders, current common newborn DNA tests only detect approximately 20 of them. We are working to address this by developing cost effective screening that identifies the phenotypes of genetic anomalies.

Our application was evaluated on thousands of pediatric patients from 28 countries with 128 different genetic conditions

Our Solution

The artificial intelligence behind our simple mobile interface has learned the phenotypes of thousands of real patients to detect genetic disorders in newborns and children

Our Solution

The artificial intelligence behind our simple mobile interface has learned the phenotypes of thousands of real patients to detect genetic disorders in newborns and children

Learn More

Provides an easy-to-use screening tool

Evaluates the risk of dysmorphology with genetic origin without assumptions about the presence of any condition

Provides quantitative facial biometrics

Supports early referral of patients to specialized testing and care

Evalutated on 128 rare diseases

Our Partners

MGeneRx works in close collaboration with the following organizations

Children's National Hospital

American Academy of Pediatrics

In the Press

The Algorithm Will See You Now: How AI is Helping Doctors Diagnose and Treat Patients

PBS NOVA NEXT

The Economist

Cosmos Magazine

National News – UAE

Ready to Learn More?

WOULD YOU LIKE TO BE A PART OF OUR ENDEAVOR TO ADDRESS DIGITAL GENETIC DISORDERS?

Developing AI based mobile applications that identify genetic disorders
in pediatric patients

Through early detection, newborn deaths and hospitalizations can be significantly reduced.

Developing AI based mobile applications that identify genetic disorders
in pediatric patients

Through early detection, newborn deaths and hospitalizations can be significantly reduced.

Developing AI based mobile applications that identify the phenotypes of genetic disorders
in pediatric patients

Through early detection, newborn deaths and hospitalizations can be significantly reduced.

MGeneRx is developing an artificial intelligence platform developed by rare disease experts, physicians and engineers that can instantly identify a child’s risk for congenital birth defects using biometric analysis.

With over 8,000 identified genetic disorders, current common newborn DNA tests only detect approximately 20 of them. We are working to address this by developing cost effective screening that identifies the phenotypes of genetic anomalies.

Our application was evaluated on thousands of pediatric patients from 28 countries with 128 different genetic conditions

With over 8,000 identified genetic disorders, current common newborn DNA tests only detect approximately 20 of them. We are working to address this by developing cost effective screening that identifies the phenotypes of genetic anomalies.

Our application was evaluated on thousands of pediatric patients from 28 countries with 128 different genetic conditions

With over 8,000 identified genetic disorders, current common newborn DNA tests only detect approximately 20 of them. We are working to address this by developing cost effective screening that identifies the phenotypes of genetic anomalies.

Our application was evaluated on thousands of pediatric patients from 28 countries with 128 different genetic conditions

Our Solution

The artificial intelligence behind our simple mobile interface has learned the phenotypes of thousands of real patients to detect genetic disorders in newborns and children

Our Solution

The artificial intelligence behind our simple mobile interface has learned the phenotypes of thousands of real patients to detect genetic disorders in newborns and children

Provides an easy-to-use screening tool

Evaluates the risk of dysmorphology with genetic origin without assumptions about the presence of any condition

Provides quantitative facial biometrics

Supports early referral of patients to specialized testing and care

Evalutated on 128 rare diseases

Our Partners

MGeneRx works in close collaboration with the following organizations

Children's National Hospital

American Academy of Pediatrics

In the Press